netFormulary NHS
North East and North Cumbria
ICS Formulary
News Title

 Last updated: 17th January 2024

Formulary Amendments
Chapter Change Reason for change
02.16 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy NICE TA913 &
04.02.01 Addition of benperidol for control of deviant antisocial sexual behaviour Formulary merger
04.09.03 Riluzole for the treatment of Motor Neuron Disease with swallowing difficulties where crushing tablets is not appropriate NENC Medicines Committee approval
07.04.05 Tadalafil 5mg daily tablets for erectile dysfunction NENC Medicines Committee approval
08.01.05 Atezolizumab - new subcutaneous formulation added NHSE SSC2560
08.01.05 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable NICE TA917 &
08.01.05 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments NICE TA927 &
08.01.05 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (NICE TA809) NHSE SSC2568
08.01.05 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, falloian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (NICE TA908) NHSE SSC2566
08.01.05 Pembrolizumab for previously treated endometrial, bilary, colorectal, gastric and small intestine cancer with high microsetellite instability or mismatch repair deficiency NICE TA914 &
08.01.05 Pembrolizumab with lenvatinib for previously treated advance or recurrent endometrial cancer (NICE TA904) NHSE SSC 2561
08.01.05 Ruxolitinib for treating polycythaemia vera NICE TA921 &
NHSE SSC 2564 Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (NICE TA903) NHSE SSC 2562 Sodium Chloride 5mmol/ml oral solution in accordance with NPPG/RCPH Position Statement NENC Medicines Committee approval
09.06.04 Adcal-D3 effervescent tablets and Cacit D3 sachets following discontinuation of Calfovit D3 effervescent granules. Merged all preparations into one calcium carbonate/colecalciferol entry  NENC Medicines Committee approval
09.08.01 Cipaglucosidase alfa (CIPA) plus miglustat for treating late-onset Pompe disease in adults. Information only NICE TA912 & NHSE SSC 2557
10.01.03 Bimekizumab for treating axial spondyloarthritis NICE TA918
10.01.03 Tofacitinib for treating active ankylosing spondylitis NICE TA920
10.02.02 Quinine sulphate for nocturnal leg cramps NENC Medicines Committee approval
12.01.01 Ciprofloxacin ear drops 0.2% for the treatment of otitis externa. Changed fron Green+ to Green NENC Medicines Committee approval
12.01.02 Otitis media with effusion in under 12s - link added NICE NG233 
13.02.01 AquaGel (oil free) lubricating jelly for the relief of dryness of the nose, lips and face when a patient is using oxygen via nasal prongs CPAP masks etc NENC Medicines Committee approval
13.08.01 Anthelios Sunscreen Lotion following the discontinuation of Sunsense NENC Medicines Committee approval Midazolam 10mg/2ml injection in palliative care. Changed from Green+ to Green NENC Medicines Committee approval